Ion Channel Modulators: A Global Strategic Business Report
San Jose, California (PRWEB) March 28, 2013
Follow us on LinkedIn – Drugs that target ion channel modulation are currently part of mainstream therapies to treat a broad range of diseases, including auto immune diseases, peripheral and central nervous system disorders, cardiovascular disorders, and metabolic disorders. Earlier limited by factors such as, insufficient understanding about ion channel physiology and transport mechanisms and lack of efficient primary screening technology, incremental technology developments have today helped ease several of the bottlenecks. The scientific community has been successful in generating large quantities of biological data pertaining to ion channels as therapeutic targets.
Technological advancements in the field of ion channel screening and the progress made in molecular understanding of the biological process are aiding in efficient, faster, and cost-effective drug development. Development of cutting edge automated electrophysiology instruments have particularly helped overthrow limitations of traditional electrophysiology like technical complexities, time consuming labor intensive screening processes, and lack of precision. Steadily expanding application areas for ion channel modulation is also expected to drive growth in the market in the coming years, as stated by the new market research report on Ion Channel Modulators. Pain management and oncology represent two of the most potent emerging therapeutic areas for Ion channels based drugs.
The global market for ion channel modulating drugs is dominated by developed countries, with the US representing the largest market, followed by Europe. Currently, around 14% of the commercial drugs in the global pharmaceutical industry are based on ion channel modulation. More drugs are expected to be commercialized in the next few years with advancements in ion channel screening technology. Currently, a large number of companies worldwide are actively engaged in the field of ion channel research and product development. Large pharma companies like GlaxoSmithKline and Pfizer and medium and small-sized biotech companies alike, are injecting significant investments into ion channel research and drug development. Small-sized companies, however, enjoy competitive advantages given their specialized expertise on specific niche areas, highly skilled teams, as well as focus on libraries of specific compounds for screening. Approximately 65% of ion channel drugs under development belong to medium to small sized companies. As a result, collaborations and partnerships, such as licensing contracts involving major pharmaceutical companies and smaller research based organizations, are rampant in the ion channel modulators space.
Major players in the market include AstraZeneca, Aurora Biomed Inc., CalciMedica Inc., Cellectricon AB, Convergence Pharmaceuticals Ltd., Cytocentrics AG, Evotec AG, flyion GmbH, GlaxoSmithKline Plc., Neusentis, Nanion Technologies GmbH, NeuroSearch, Novartis AG, Parion Sciences Inc., Pfizer Inc., Sanofi, Targacept Inc., Xention Limited, and Zalicus Inc., among others.
The research report titled “Ion Channel Modulators: A Global Strategic Business Report” announced by the Global Industry Analysts Inc., provides a comprehensive review of market trends, key growth drivers, issues and concerns, future prospects, new product launches, strategic corporate deals, and profiles of major and niche global as well as regional market participants. The report provides market estimates and projections in US$ for all major geographic markets including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, Latin America, and Rest of World.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/